Physician profile
Fung Lam
NPI 1649608951
$5,776.22
in general payments reported to CMS, 2019-2025
15 companies · $914 in 2025
The $914 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $794 · 2022: $1,575 · 2023: $939 · 2024: $1,555 · 2025: $914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,407.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,565.50 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $899.80 | 2021-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $820.05 | 2021-2025 | Lokelma, Farxiga, Wainua |
| Novartis Pharmaceuticals Corporation | $647.16 | 2022-2025 | |
| Pfizer INC. | $572.62 | 2021-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $245.29 | 2021-2022 | |
| Irhythm Technologies, INC. | $200.40 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| E.R. Squibb & Sons, L.L.C. | $179.38 | 2021-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.69 | 2022-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $163.48 | 2021-2024 | Xarelto |
| Lilly USA, LLC | $126.84 | 2023-2024 | Mounjaro, Zepbound |
| Philips North America LLC | $71.28 | 2024-2025 | (Ck4) Mcot, Mcot |
| Shockwave Medical, INC | $50.51 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave E8 Peripher |
| Alnylam Pharmaceuticals INC. | $30.85 | 2025 | Onpattro |
| Esperion Therapeutics, INC. | $29.37 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fung Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.